Ingrezza Shortage: What Providers and Prescribers Need to Know in 2026

When patients call your office saying they can't fill their Ingrezza prescription, it's rarely because the drug is physically unavailable. As of 2026, Ingrezza (valbenazine) is not on the FDA's official drug shortage list — but access challenges are real and complex. This guide covers what prescribers need to understand to effectively manage Ingrezza access for their patients.

Current Ingrezza Supply Status (2026)

Ingrezza is not on the FDA Drug Shortage Database as of 2026. Neurocrine Biosciences manufactures valbenazine without reported supply chain disruptions. The medication is available through Neurocrine's specialty pharmacy network. According to Neurocrine's own data (as of mid-2025), coverage is approved for more than 8 in 10 patients nationwide.

Despite these positive statistics, individual patients frequently experience access delays. The barriers are systemic — not related to manufacturing — and understanding them is essential to advocating effectively for your patients.

The Three Main Access Barriers Clinicians Face

1. Specialty Pharmacy Distribution Model

Ingrezza is exclusively dispensed through a select network of specialty and local affiliated pharmacies. Prescriptions sent to retail pharmacies will not be filled. Your practice's prescription workflow must account for this — a standard e-prescription sent to a retail pharmacy will result in a dispense failure and a call from a frustrated patient.

The most reliable approach: use the INGREZZA Treatment Form (available from Neurocrine Access Support), which simultaneously prescribes Ingrezza and enrolls the patient in the support program. This single form routes directly to specialty pharmacy and triggers PA support and copay assistance enrollment.

2. Prior Authorization Requirements

Virtually every payer requires prior authorization for Ingrezza — commercial, Medicare, and Medicaid alike. PA criteria typically include:

Confirmed diagnosis of tardive dyskinesia or chorea associated with Huntington's disease

Adult patient (18 years or older)

Prescriber is a specialist (neurologist, psychiatrist, or movement disorder specialist) for initial authorization on some plans

Some plans require prior trial and failure of another VMAT2 inhibitor (step therapy)

Tip: Neurocrine's Regional Patient Access Managers (RPAMs) can assist your practice navigate PA for specific payers. Consider building a PA workflow template for Ingrezza to expedite future requests.

3. Formulary Placement and Step Therapy

Some payers — particularly Medicare Part D plans and certain commercial plans — have placed either Ingrezza or Austedo (deutetrabenazine) as the non-preferred VMAT2 inhibitor, requiring trial of the preferred agent first. If your patient was approved for Ingrezza but your plan requires Austedo first, you can file a medical necessity exception letter. Document why the patient requires Ingrezza specifically — for example, inability to take the drug with food (Austedo requirement), or a history of intolerance to deutetrabenazine.

Managing Patients Who Can't Get Ingrezza Immediately

If a patient has been prescribed Ingrezza but is facing a delay:

Bridge therapy option: Enroll the patient in the 30-Day Free Trial (INGREZZA Start Program). Your office submits the enrollment form and the patient receives a free 1-month supply while PA is being processed.

Appeal support: Neurocrine's RPAMs can help with peer-to-peer review requests and PA appeal letters.

Alternative VMAT2 therapy: If Ingrezza cannot be obtained quickly, consider whether Austedo XR (deutetrabenazine once daily) is a viable bridge.

How medfinder Helps Your Patients

For patients who need help locating a pharmacy that can fill their Ingrezza, medfinder is a service that calls pharmacies on behalf of your patients to identify which ones can fill the prescription. Referring patients to medfinder can save significant time for both patient and staff. Patients provide their medication, dose, and location — and medfinder delivers results via text.

Neurocrine Access Support: Your Office Partner

Phone: 1-844-647-3992 (Monday–Friday, 8 am–8 pm ET)

Resources: PA support, Treatment Form submission, patient assistance enrollment, 30-Day Free Trial enrollment, peer-to-peer review coordination

Also see our companion guide: How to help your patients find Ingrezza in stock: A provider's guide.